IBA (Ion Beam Applications SA), Louvain-la-Neuve, Belgium, a manufacturer of proton therapy systems for the treatment of cancer, has received marketing authorization from the FDA for its Compact Gantry Beam Line. IBA anticipates that this regulatory approval will increase interest in its Proteus ONE proton therapy system.
The Proteus ONE is a single-room proton therapy system. According to IBA, it is smaller, less expensive, faster to install than other systems. The system delivers the proton beam to a tumor using Pencil Beam Scanning, a proton beam delivery mode that “paints the target volume, one layer at a time, pixel by pixel, to precisely match the shape of the tumor.”
IBA to date has placed five Proteus ONE systems in facilities around the world, including one in the Willis-Knighton Cancer Center in Shreveport, La.